CHICAGO, Illinois, August 24, 2016 – KMR Group, a leader in analyzing R&D performance data for the biopharmaceutical R&D industry, recently concluded an assessment of global Industry site contract cycle times. The study evaluated 20,000 recently-executed contracts for Phase II and III trials from leading biopharmaceutical companies.
KMR Group’s Site Contracts Study found that overall site contract cycle times have doubled from an Industry median of about 1.5 months in 2010-2011 to over 3 months in 2014-2015. Even contracts conducted in North America, traditionally a top performer, have increased from 1.3 in 2010-11 to 2.4 in 2014-15. Emerging markets continue to have longer cycle times. Additionally Oncology trials typically have the longest site contracts cycle time compared to trials for other therapy areas.
The study examined site contract performance in many ways, comparing study phase, type of site (independent, institution), budget cycle time, regulatory document cycle time, therapy area, region and country level performance, and use of master agreements. The analysis showed each company’s performance ranked against other major companies in the Industry, and it also provided context on more qualitative site contracting practices such as outsourcing use, payment strategies, timing, and terms.
“This type of information is invaluable for setting study timelines, as well as assessing areas of performance opportunity. The study gave participants reliable benchmarks and detailed company performance information that they can directly incorporate into site contracting strategies,” commented Melissa Hutchens, Senior Consultant at KMR Group.
For further information on future rounds of the Site Contracts Study contact:
Lyndsey McKay, Marketing and Communications Manager
Tel: +1 (312) 795-0400
Email: lmckay [at] kmrgroup.com
About KMR
KMR Group has worked exclusively in biopharmaceutical R&D since the early 1990s. KMR Group is an industry leader in benchmarking, analytics and performance management as well as a developer of on-line analytics tools that enable access to our propriety and rich datasets. KMR's clinical platform contains the most reliable source for trial performance, recruitment and site metrics data, with over 25,000 global clinical trials. Clients depend on these tools to benchmark performance, define recruitment strategies and shape enrollment plans and to identify best performing sites. For more information or for a demonstration of any of KMR's tools, please contact us.
Visit our website at https://kmrgroup.com
Follow us on Twitter @KMRGroupInc
KMR Group’s Site Contracts Study found that overall site contract cycle times have doubled from an Industry median of about 1.5 months in 2010-2011 to over 3 months in 2014-2015. Even contracts conducted in North America, traditionally a top performer, have increased from 1.3 in 2010-11 to 2.4 in 2014-15. Emerging markets continue to have longer cycle times. Additionally Oncology trials typically have the longest site contracts cycle time compared to trials for other therapy areas.
The study examined site contract performance in many ways, comparing study phase, type of site (independent, institution), budget cycle time, regulatory document cycle time, therapy area, region and country level performance, and use of master agreements. The analysis showed each company’s performance ranked against other major companies in the Industry, and it also provided context on more qualitative site contracting practices such as outsourcing use, payment strategies, timing, and terms.
“This type of information is invaluable for setting study timelines, as well as assessing areas of performance opportunity. The study gave participants reliable benchmarks and detailed company performance information that they can directly incorporate into site contracting strategies,” commented Melissa Hutchens, Senior Consultant at KMR Group.
For further information on future rounds of the Site Contracts Study contact:
Lyndsey McKay, Marketing and Communications Manager
Tel: +1 (312) 795-0400
Email: lmckay [at] kmrgroup.com
About KMR
KMR Group has worked exclusively in biopharmaceutical R&D since the early 1990s. KMR Group is an industry leader in benchmarking, analytics and performance management as well as a developer of on-line analytics tools that enable access to our propriety and rich datasets. KMR's clinical platform contains the most reliable source for trial performance, recruitment and site metrics data, with over 25,000 global clinical trials. Clients depend on these tools to benchmark performance, define recruitment strategies and shape enrollment plans and to identify best performing sites. For more information or for a demonstration of any of KMR's tools, please contact us.
Visit our website at https://kmrgroup.com
Follow us on Twitter @KMRGroupInc
